ReviewInnere Medizin (Heidelberg, Germany)2026
[Computed tomography in cardiology: its necessity and developments].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac computed tomography angiography (CCTA) has evolved in recent years into a central pillar of non-invasive cardiovascular diagnostics and is now firmly established in both clinical guidelines and everyday practice. In particular, it plays a key role as a first-line modality for ruling out coronary artery disease in patients with low to intermediate pretest probability. In the acute setting, it can also be used in selected patient populations for rapid and reliable exclusion of disease, thereby improving patient management in the emergency department. Beyond the assessment of luminal stenosis, CCTA enables a comprehensive characterization of coronary atherosclerosis. Plaque volume and composition have emerged as key prognostic factors. Modern post-processing techniques allow for increasingly standardized and quantitative analyses, supporting individualized risk stratification and treatment planning. Notably, the detection of subclinical atherosclerosis can facilitate early initiation of preventive strategies and improve patient adherence to therapy. Technological advances such as photon-counting CT, and AI-based plaque analysis have significantly expanded diagnostic capabilities. In addition, CCTA plays an important role in patients after revascularization and in the planning and follow-up of structural heart interventions. Overall, it represents a powerful and versatile imaging modality that substantially enhances diagnosis, risk assessment, and therapeutic decision-making in modern cardiology.
Indexed as
Identifiers
42439908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.